Gueven, N, Idebenone for Leber's hereditary optic neuropathy, Drugs of today, 52, (3) pp. 173-181. ISSN 1699-3993 (2016) [Refereed Article]
Copyright 2016 Prous Science, S.A.U.
Idebenone is a rapidly absorbed, safe and well-tolerated drug and is currently the only clinically proven treatment option for Leber's hereditary optic neuropathy (LHON) patients. Idebenone (Raxone®) is approved by the European Medicines Agency for the treatment of LHON and has been available on the European market since 2015. Due to its molecular mode of action of bypassing the defective mitochondrial complex I, idebenone leads to improved energy supply and a functional recovery of retinal ganglion cells during the acute stage of the disease, thereby preventing further vision loss and promoting recovery of vision. Thus, commencing treatment shortly after the onset of symptoms is likely to have the best therapeutic effect, a hypothesis that is supported by the available clinical data.
|Item Type:||Refereed Article|
|Keywords:||genetic disorders, idebenone, inherited mitochondrial respiratory chain diseases, LHON, Leberís hereditary optic neuropathy, metabolic diseases|
|Research Division:||Medical and Health Sciences|
|Research Group:||Pharmacology and Pharmaceutical Sciences|
|Research Field:||Clinical Pharmacology and Therapeutics|
|Objective Division:||Expanding Knowledge|
|Objective Group:||Expanding Knowledge|
|Objective Field:||Expanding Knowledge in the Biological Sciences|
|Author:||Gueven, N (Dr Nuri Guven)|
|Web of Science® Times Cited:||2|
Repository Staff Only: item control page